Detalhe da pesquisa
1.
Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first-line systemic treatment or best supportive care: A multicenter international study.
Eur J Haematol
; 109(1): 58-68, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35298049
2.
The myeloid sarcoma treated by Venetoclax with hypomethylating agent followed by stem cell transplantation: rare case report.
BMC Womens Health
; 21(1): 184, 2021 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33933047
3.
Shift of N-MYC Oncogene Expression in AML Patients Carrying the FLT3-ITD Mutation.
Pathophysiology
; 30(3): 296-313, 2023 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37606386
4.
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML.
Blood Adv
; 6(17): 5132-5145, 2022 09 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35728048
5.
Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy.
Leuk Lymphoma
; 63(4): 928-938, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35147482
6.
Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial.
Blood Adv
; 6(14): 4147-4156, 2022 07 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-35413116
7.
Rapid Efficacy of Gemtuzumab Ozogamicin in Refractory AML Patients with Pulmonary and Kidney Failure.
Biology (Basel)
; 9(2)2020 Feb 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32050707